Free Trial

SkinBioTherapeutics (LON:SBTX) Trading 10.6% Higher - Should You Buy?

SkinBioTherapeutics logo with Medical background

SkinBioTherapeutics plc (LON:SBTX - Get Free Report) was up 10.6% during trading on Tuesday . The stock traded as high as GBX 23.50 ($0.31) and last traded at GBX 23.50 ($0.31). 1,576,604 shares were traded during mid-day trading, an increase of 46% from the average session volume of 1,077,583 shares. The stock had previously closed at GBX 21.25 ($0.28).

SkinBioTherapeutics Stock Up 3.4 %

The company has a market cap of £59.62 million, a price-to-earnings ratio of -16.05 and a beta of 2.01. The stock has a 50-day simple moving average of GBX 21.51 and a 200-day simple moving average of GBX 18.18. The company has a current ratio of 0.93, a quick ratio of 10.01 and a debt-to-equity ratio of 27.57.

SkinBioTherapeutics (LON:SBTX - Get Free Report) last released its earnings results on Wednesday, March 26th. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

About SkinBioTherapeutics

(Get Free Report)

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.

Read More

Should You Invest $1,000 in SkinBioTherapeutics Right Now?

Before you consider SkinBioTherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SkinBioTherapeutics wasn't on the list.

While SkinBioTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

7 Cybersecurity Stocks Outperforming the Market Right Now
Markets in Rally Mode: Will Earnings Keep It Going?
3 Tech Stocks to Buy Now—And 3 You’ll Regret Keeping

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines